Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Adicet Bio, Inc. (ACET) - free report >>
Krystal Biotech, Inc. (KRYS) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adicet Bio, Inc. (ACET) - free report >>
Krystal Biotech, Inc. (KRYS) - free report >>
Image: Bigstock
New Strong Sell Stocks for May 28th
Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:
Adicet Bio, Inc. (ACET - Free Report) is a biopharmaceutical company that discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The Zacks Consensus Estimate for its current year earnings has been revised 10% downward over the last 30 days.
Fury Gold Mines Limited (FURY - Free Report) operates as an exploration and development company. The Zacks Consensus Estimate for its current year earnings has been revised 44.4% downward over the last 30 days.
Krystal Biotech, Inc. (KRYS - Free Report) is a clinical stage biotechnology company that engages in the field of redosable gene therapy to treat serious rare diseases. The Zacks Consensus Estimate for its current year earnings has been revised 22.5% downward over the last 30 days.
Mersana Therapeutics, Inc. (MRSN - Free Report) is a clinical stage biopharmaceutical company that focuses on the development of antibody drug conjugates. The Zacks Consensus Estimate for its current year earnings has been revised 16.4% downward over the last 30 days.
NewAge, Inc. develops, markets, sells, and distributes healthy products. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.
View the entire Zacks Rank #5 List.